Palatin Technologies (LTS:0KF3) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Palatin Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Palatin Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of Palatin Technologies's Risk Assessment

For the Biotechnology subindustry, Palatin Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palatin Technologies's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Risk Assessment falls into.

Palatin Technologies (LTS:0KF3) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Palatin Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Palatin Technologies (LTS:0KF3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (LTS:0KF3) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

PTN:USA PTN:Germany PTN:Germany

Address

4B Cedar Brook Drive, Cranbury, NJ, USA, 08512

Website

https://www.palatin.com

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Palatin Technologies (LTS:0KF3) Headlines

No Headlines